September 24, 2015
Paul E. Sax, M.D., is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.
The big ID story the past couple of weeks is that the price of pyrimethamine -- a drug that's been available generically for decades -- went from $13.50 to $750 for one pill after the exclusive rights to the drug were purchased by Turing Pharmaceuticals.
Now, after a barrage of criticism -- all the way from this little blog to the Infectious Diseases Society of America to the New York Times to the leading Democratic candidate for President -- the company has wisely decided to lower the price.
Exactly what the price will be remains to be seen, because there's a lot of space between $13.50 and $750, but we'll find out soon enough.
How about defense of the initial decision to raise the price?
There are a bunch of claims here that don't quite ring quite true.
The part around 2'30", however, is undeniably true:
Profits are a great thing to maintain your corporate existence.
Look, there is nothing wrong with companies making profits for discovering, developing, and creating good products -- this is a capitalist country, after all, and innovation should be rewarded. I write that sentence keenly aware that the new iPhones are about to appear in stores this weekend, and yes, my iPhone 4 is looking a little tired.
But with the pyrimethamine price increase, some sort of threshold of reasonableness was passed.
The negative response has been essentially universal, and quite appropriate.
Paul Sax is Clinical Director of Infectious Diseases at Brigham and Women's Hospital. His blog HIV and ID Observations is part of Journal Watch, where he is Editor-in-Chief of Journal Watch AIDS Clinical Care.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.